No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
www.galderma.comNo one on the platform currently holds GALD.SW.
No tracked institution reports a position in GALD.SW as of their last filing.
No one on the platform has traded GALD.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.3% | — | — | — | ||
| Rev. Growth % | 7.2% | |||||
| Profit Margin % | 12.3% | 1.8% | ||||
| Free Cash Flow Margin % | 19.7% | 5.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.6B | +26.5% | $4.94 | $4.33–$5.21 | — | 10 |
| 2027 | $7.7B | +17.0% | $6.77 | $6.59–$6.80 | — | 12 |
| 2028 | $8.9B | +15.6% | $8.65 | $7.45–$10.06 | — | 9 |
| 2029 | $10.2B | +14.2% | $10.76 | $10.48–$11.07 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $2.25 | $2.34 | +4.0% |
| 2026-03-05 | $1.57 | $2.03 | +29.3% |
| 2025-07-24 | $1.16 | $1.39 | +19.8% |
| 2025-03-06 | $0.89 | $1.20 | +34.8% |
| 2024-10-24 | $0.90 | $0.11 | -87.6% |
| 2024-07-25 | $1.12 | $0.55 | -50.9% |
| $4.5B |
| — |
| GMI.SWGroupe Minoteries S.A. | $228.00 | +0.88% | $75M | — |
| LISN.SWChocoladefabriken Lindt & Sprüngli AG | $89200.00 | -0.45% | $20.0B | — |
Source: Financial Modeling Prep · peers by sector/industry